Reflux Esophagitis (Gastroesophageal Reflux Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Gastroesophageal reflux disease (GERD) is when the liquid content of the stomach refluxes into the esophagus, that condition. It is a chronic condition. The symptoms of GERD are nausea, heartburn and vomiting. The predisposing factors include eating large meals, which can cause the Lower Esophageal Sphincter (LES) to open inappropriately, as well as obesity, pregnancy, greasy food and certain drugs.
The GERD research report provides a comprehensive overview on the therapeutics under development for GERD, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for GERD and features dormant and discontinued projects.
Key targets in the Reflux Esophagitis Pipeline Drugs Market
Key targets in the Reflux Esophagitis pipeline drugs market are Potassium Transporting ATPase Alpha Chain 1 (Gastric H(+)/K, Gastrin/Cholecystokinin Type B Receptor, Bone Morphogenetic Protein 2, Bone Morphogenetic Protein 4, Gastrin, and Orexin Receptor Type 1.
Reflux Esophagitis Pipeline Drugs Market, by Target
For more target insights, download a free report sample
Key MoA in the Reflux Esophagitis Pipeline Drugs Market
Key MoA in the Reflux Esophagitis pipeline drugs market are Potassium Transporting ATPase Alpha Chain 1 (Gastric H(+)/K, Gastrin/Cholecystokinin Type B Receptor Inhibitor, Bone Morphogenetic Protein 2 Inhibitor, Bone Morphogenetic Protein 4 Inhibitor, Gastrin Inhibitor, and Orexin Receptor Type 1 Inhibitor.
Reflux Esophagitis Pipeline Drugs Market, by MoA
To get more insights on key MoA, download a free report sample
Key Routes of Administration in the Gastroesophageal Reflux Disease Pipeline Drugs Market
The key routes of administration in the Reflux Esophagitis pipeline drugs market are oral, parenteral, intravenous, and intramuscular.
Gastroesophageal Reflux Disease Pipeline Drugs Market, by RoA
To get more insights on key RoA, download a free report sample
Key Molecule Types in the Gastroesophageal Reflux Disease Pipeline Drugs Market
The key molecule types in the Reflux Esophagitis pipeline drugs market are small molecule, conjugate vaccine, and monoclinal antibody.
Gastroesophageal Reflux Disease Pipeline Drugs Market, by Molecule Type
To get more insights on key molecule types, download a free report sample
Major Companies in the Reflux Esophagitis (Gastroesophageal Reflux Disease) Pipeline Drugs Market
The major companies in the Reflux Esophagitis (Gastroesophageal Reflux Disease) pipeline drugs market are HK inno.N Corp, Addpharma Inc (Addpharma), Ahn-Gook Pharmaceutical Co Ltd, CalyGene Biotechnology Inc, Daewoong Co Ltd, CalyGene Biotechnology Inc, Hanmi Pharmaceuticals Co Ltd, and Eisai Co Ltd.
Reflux Esophagitis (Gastroesophageal Reflux Disease) Pipeline Drugs market, by Company
For more company insights, download a free report sample
Reflux Esophagitis Market Overview
| Key Targets | Potassium Transporting ATPase Alpha Chain 1 (Gastric H(+)/K, Gastrin/Cholecystokinin Type B Receptor, Bone Morphogenetic Protein 2, Bone Morphogenetic Protein 4, Gastrin, and Orexin Receptor Type 1 |
| Key MoA | Potassium Transporting ATPase Alpha Chain 1 (Gastric H(+)/K, Gastrin/Cholecystokinin Type B Receptor Inhibitor, Bone Morphogenetic Protein 2 Inhibitor, Bone Morphogenetic Protein 4 Inhibitor, Gastrin Inhibitor, and Orexin Receptor Type 1 Inhibitor |
| Key RoA | Oral, Parenteral, Intravenous, And Intramuscular |
| Key Molecule Types | Small Molecule, Conjugate Vaccine, and Monoclinal Antibody |
| Key Companies | HK inno.N Corp, Addpharma Inc (Addpharma), Ahn-Gook Pharmaceutical Co Ltd, CalyGene Biotechnology Inc, Daewoong Co Ltd, CalyGene Biotechnology Inc, Hanmi Pharmaceuticals Co Ltd, and Eisai Co Ltd |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of respiratory syncytial virus infections (infectious disease).
- The pipeline guide reviews pipeline therapeutics for Reflux Esophagitis (Gastroesophageal Reflux Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Reflux Esophagitis (Gastroesophageal Reflux Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates respiratory syncytial virus infections (infectious disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Reflux Esophagitis (Gastroesophageal Reflux Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counter-strategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Reflux Esophagitis (Gastroesophageal Reflux Disease)
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Reflux Esophagitis (Gastroesophageal Reflux Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Ahn-Gook Pharmaceutical Co Ltd
CalyGene Biotechnology Inc
Cancer Advances Inc
Changchun Serene Pharmaceutical Co Ltd
Chong Kun Dang Pharmaceutical Corp
Cinclus Pharma AG
Daewoong Co Ltd
Eisai Co Ltd
EsoCap AG
Hana Pharm Co Ltd
Hanmi Pharmaceuticals Co Ltd
HK inno.N Corp
Ilyang Pharmaceutical Co Ltd
ISOThrive Inc
Jiangsu Carephar Pharmaceutical Co Ltd
Korea Pharma Co Ltd
Korea United Pharm Inc
Onconic Therapeutics Co Ltd
RaQualia Pharma Inc
Renexxion LLC
Sun Pharma Advanced Research Company Ltd
Takeda Pharmaceutical Co Ltd
Trio Medicines Ltd
Xiamen Encheng Pharmaceutical Co Ltd
XuanZhu Biological Technology Co Ltd
Yooyoung Pharm Co Ltd
Yuhan Corp
Yungjin Pharm Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Reflux Esophagitis (Gastroesophageal Reflux Disease) pipeline products market?
The key targets in the Reflux Esophagitis (Gastroesophageal Reflux Disease) pipeline products market are Potassium Transporting ATPase Alpha Chain 1 (Gastric H(+)/K, Gastrin/Cholecystokinin Type B Receptor, Bone Morphogenetic Protein 2, Bone Morphogenetic Protein 4, Gastrin, and Orexin Receptor Type 1.
-
What are the key MoA in the Reflux Esophagitis (Gastroesophageal Reflux Disease) pipeline products market?
Some of the key MoA in the Reflux Esophagitis (Gastroesophageal Reflux Disease) pipeline products market are Potassium Transporting ATPase Alpha Chain 1 (Gastric H(+)/K, Gastrin/Cholecystokinin Type B Receptor Inhibitor, Bone Morphogenetic Protein 2 Inhibitor, Bone Morphogenetic Protein 4 Inhibitor, Gastrin Inhibitor, and Orexin Receptor Type 1 Inhibitor.
-
What are the key routes of administration in the Reflux Esophagitis (Gastroesophageal Reflux Disease) pipeline products market?
The key routes of administration in the Reflux Esophagitis (Gastroesophageal Reflux Disease) pipeline products market are oral, parenteral, intravenous, and intramuscular.
-
What are the key molecule types in the Reflux Esophagitis (Gastroesophageal Reflux Disease) pipeline products market?
The key molecule types in the Reflux Esophagitis (Gastroesophageal Reflux Disease) pipeline products market are small molecule, conjugate vaccine, and monoclinal antibody.
-
What are the major companies in the Reflux Esophagitis (Gastroesophageal Reflux Disease) pipeline drugs market?
The major companies in the Reflux Esophagitis (Gastroesophageal Reflux Disease) pipeline drugs market are HK inno.N Corp, Addpharma Inc (Addpharma), Ahn-Gook Pharmaceutical Co Ltd, CalyGene Biotechnology Inc, Daewoong Co Ltd, CalyGene Biotechnology Inc, Hanmi Pharmaceuticals Co Ltd, and Eisai Co Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Other Diseases reports